Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kai Wang"'
Autor:
Raymond T. Chung, Tuo Shao, Peng An, Kai Wang, Lingyan Duan, Hao Wang, Yingying Yu, Fudi Wang, Xuexian Fang, Shufen Wang, Li Jiang, Qi Cheng, Junxia Min, Shusen Zheng, Qian Wu, Jiaming Wang, Pan Zhang, Zhe Shen
Publikováno v:
Blood
Although the serum-abundant metal-binding protein transferrin (encoded by the Trf gene) is synthesized primarily in the liver, its function in the liver is largely unknown. Here, we generated hepatocyte-specific Trf knockout mice (Trf-LKO), which are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81a2403c72685129f524da78631e2bfb
https://europepmc.org/articles/PMC7414596/
https://europepmc.org/articles/PMC7414596/
Autor:
Haichan Xu, Biljana Horn, Rui Zhang, Sanfang Tu, Le-Ping Zhang, Cheng Jiao, Yu-Chen Liu, Yuan Sun, Yuhua Li, Yoshiyuki Takahashi, Zhouyang Liu, Bin Wang, Jia Feng, Yuchen Li, Lung-Ji Chang, Xue Song, Yi-Fei Cheng, Yongping Zhang, Huyong Zheng, Juan Xiao, Kai Wang, Nobuhiro Nishio
Publikováno v:
Blood. 136:7-7
BACKGROUND: Allogeneic haematopoietic stem cell transplantation (allo-HCT) is a standard treatment for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). However ~30-40% of patients (pts) still relapse after HCT. We report a cohort
Autor:
Brian A Walker, Fadi Towfic, Mehmet Kemal Samur, In Sock Jang, Nikhil C. Munshi, Cody Ashby, Anjan Thakurta, Kai Wang, Erin Flynt, Maria Ortiz, Gareth J. Morgan, Matthew Trotter
Publikováno v:
Blood. 132:3165-3165
There is currently no standard approach to classify high-risk newly diagnosed Multiple Myeloma (ndMM). Various efforts have yielded approaches based on single molecular data types, including gene expression (GE), mutation (SNV), copy number alteratio
Autor:
Xiao-Li Zheng, Lung-Ji Chang, Yu-Chen Liu, Li Liu, Kai Wang, Dong Li, Dao-Pei Lu, Ya-Chen Li, Jian-Ping Zhang, Le-Ping Zhang, Huyong Zheng, Zhi-Yong Gao, Jing-Bo Wang, Shih-Ting Tsao, Xun Lai, Lujia Dong, Heng-Xiang Wang, Xi-You Tan, Yu-Ming Ying
Publikováno v:
Blood. 128:587-587
Background: CD19 chimeric antigen receptor (CAR)-modified T cell therapy has demonstrated clinical efficacy but often associated with severe adverse effects manifested by cytokine release syndrome (CRS). To increase safety and efficacy of CAR T thera
Autor:
Kai Wang, Doron Lipson, Deborah Morosini, Juliann Chmielecki, Adrienne Johnson, Siraj M. Ali, Norma Alonzo Palma, Roman Yelensky, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller
Publikováno v:
Blood. 124:1684-1684
Background: Non-Hodgkin lymphoma (NHL) is a large group of hematolymphoid malignant neoplasms that can occur at any age. Genomic alterations of histone modifying genes and the NF-kB signaling pathway are characteristic of NHLs. Histone deacetylase an
Autor:
Michelle Nahas, Ewelina Protomastro, Pritish K. Bhattacharyya, Kar Fai Chow, Roman Yelensky, Jie He, Gabriella Gadaleta, Jeffrey S. Ross, Coleen Bejot, Vincent A. Miller, Doron Lipson, Anthony R. Mato, Phil Stephens, Andre Goy, Kai Wang, Alan P Skarbnik, Geoff Otto, Tania Zielonka, Andrew L. Pecora, Tatyana Feldman
Publikováno v:
Blood. 124:3033-3033
Background: The survival of mantle cell lymphoma (MCL) has improved (median OS now >5 years) due to the use of dose-intensive strategies in younger patients (pts) achieving a deeper and earlier response (including molecular CR) and the application of
Autor:
Hani Hassoun, Ross L. Levine, David J. Chung, Minal Patel, Ahmet Dogan, Eric M. Sanford, Vincent A. Miller, Michelle Nahas, Sergio Giralt, Roman Yelensky, Doron Lipson, Mithat Gonen, Marcel R.M. van den Brink, Geoff Otto, Tim Brennan, Kristina W. Brennan, Kaitlyn Redling, Nikoletta Lendvai, Alexander M. Lesokhin, Heather Landau, Philip J. Stephens, Kai Wang, Guenther Koehne
Publikováno v:
Blood. 122:755-755
Background Patients with multiple myeloma (MM) have realized improved survival with the development of multi-drug combinations using immunomodulatory drugs (IMiDs), proteasome inhibitors, and alkylating agents. Nevertheless, all MM patients eventuall
Autor:
Doron Lipson, Michelle Nahas, Kai Wang, Kristina M. Knapp, Virginia M. Klimek, Sean M. Devlin, Eric M. Sanford, Tim Brennan, Marcel R.M. van den Brink, Vincent A. Miller, Alan H. Shih, Emily K. Dolezal, Geoff Otto, Stephen D. Nimer, Ross L. Levine, Philip J. Stephens, Roman Yelensky
Publikováno v:
Blood. 122:2791-2791
Although DNA methyltransferase Inhibitor (DNMTI) therapy demonstrates efficacy in patients (pts) with Myelodysplastic Syndromes (MDS), to date there are no clinical or genomic markers to select patients most likely to benefit from DNMTI therapy. Two
Autor:
Kai Wang, Molly Maloy, Philip J. Stephens, Ann A. Jakubowski, Michelle Nahas, Roman Yelensky, Marcel R.M. van den Brink, Geoff Otto, Kristina M. Knapp, Ross L. Levine, Vincent A. Miller, Alan M. Hanash, Sean M. Devlin, Doron Lipson
Publikováno v:
Blood. 122:2096-2096
Disease relapse remains the greatest cause of mortality following allogeneic stem cell transplantation (SCT). Improved predictive markers are needed to identify patients most likely to benefit from SCT. Several mutations reported recently in MDS and
Autor:
Andrei V. Krivtsov, Wang Xujun, Noushin Rahnamay Farnoud, Michael Hadler, Kristina M. Knapp, Eytan M Stein, Martin S. Tallman, Amy L Donahue, Doron Lipson, Michelle K. Nahas, Philip J. Stephens, Eric M Sanford, Kai Wang, Garrett M Frampton, Tim Brennan, Geoff A. Otto, Roman Yelensky, Vincent A. Miller, Ross L. Levine, Scott A. Armstrong
Publikováno v:
Blood. 122:1328-1328
Xenotransplantation of primary AML samples into immunodeficient mice (PDX models) represents a unique opportunity for pre-clinical testing on a group of primary human samples that possess defined genetic lesions. However, given our recent recognition